Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COPD, Chronic Obstructive Pulmonary Disease Clear all
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 6, 2026, 1:16 PM EDT
Completed No phase listed Observational

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

NCT06744374
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF, MITT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
22,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

NCT03240575
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02700919
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BCT197, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 6, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Bronchitis and Emphysema Advice and Training to Reduce Hospitalization

NCT00395083
View directory record Official record
Conditions
COPD, Emphysema
Interventions
COPD Self-management Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 6, 2026, 1:16 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

NCT01043601
View directory record Official record
Conditions
COPD
Interventions
Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars

NCT02638194
View directory record Official record
Conditions
COPD
Interventions
Active smoking of Tobacco Hookah for 2 hours, Exposure to tobacco hookah second hand smoke, Visit a win bar
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

NCT00347659
View directory record Official record
Conditions
Pulmonary Emphysema
Interventions
BLVR System
Drug
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Anti-Platelets in Chronic Obstructive Pulmonary Disease

NCT05567562
View directory record Official record
Conditions
COPD, Emphysema, Emphysema or COPD
Interventions
dual anti-platelet therapy, Placebo
Combination Product · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 6, 2026, 1:16 PM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Capnometry-Assisted Breathing Training for COPD

NCT03457103
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Capnometry-Assisted Training for COPD to Slow the Breath (CATCH), Pulmonary Rehabilitation (PR)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 6, 2026, 1:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

NCT03331302
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized Xenon-129 MRI (Experimental), Radioactive Xenon-133 scintigraphy (Active Comparator)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Prospective Study Comparing Different Modalities of Oxygen Delivery During Assessment of Functional Exercise Capacity

NCT00484562
View directory record Official record
Conditions
COPD
Interventions
Standard oxygen delivery system, Homefill oxygen delivery system, Helios oxygen delivery system, FreeStyle oxygen system
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02786927
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
22
States / cities
Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 6, 2026, 1:16 PM EDT
Completed No phase listed Observational

Lung HIV Disease in a Large Cohort-Pitt

NCT01326572
View directory record Official record
Conditions
Pulmonary Disease, HIV, Emphysema
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 6, 2026, 1:16 PM EDT
Terminated Not applicable Interventional

Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

NCT04654481
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Cough, Covid19
Interventions
HCFWO, Standard Care Plus Monitoring
Device · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Not applicable Interventional

A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients

NCT03814980
View directory record Official record
Conditions
COPD, Emphysema
Interventions
mindful breathing application, application on a computer tablet
Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00106080
View directory record Official record
Conditions
Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
Interventions
Audit and Feedback
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 6, 2026, 1:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COPD Care Pathway Among Patients With Cancer

NCT05984680
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lung Cancer, Head and Neck Cancer
Interventions
Observational Phase 1, Observational Phase 2, Group I, Observational Phase 2, Group II, Observational Phase 3
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01009463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
94
States / cities
Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316913
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Jasper, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 6, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

NCT00984659
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone propionate/salmeterol combination product, Salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Jasper, Alabama • Mobile, Alabama • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 6, 2026, 1:16 PM EDT
Completed No phase listed Observational

Factors That Affect the Development of COPD Symptoms

NCT00740337
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 6, 2026, 1:16 PM EDT